Takeda Launches $900M Overhaul to Combat Profit Decline

Takeda Launches $900M Overhaul to Combat Profit Decline

Takeda Pharmaceutical Company Limited is embarking on a significant restructuring initiative, aiming to bolster its core operating profit margin beyond 30%. This strategic move comes after the company experienced a sharp decline in annual profit, reporting a 54.6% drop to 144.1 billion yen (approximately $863 million) for the fiscal year, compared to the previous year. Despite the profit slump, the company's revenue increased by 5.9%.

The restructuring plan, set to unfold in fiscal year 2024, will involve an estimated 140 billion yen ($900 million) in one-time costs. Takeda intends to enhance efficiency and reduce expenses through workforce optimization, simplification of divisional structures, and prioritization of its research and development (R&D) portfolio. Investments will be directed towards technology, data, and digital capabilities, with the expectation of improving the profit margin by 100 to 250 basis points annually from fiscal 2025 onwards.

Challenges faced by Takeda include the loss of exclusivity on key drugs such as the blood pressure medication Azilva and the ADHD treatment Vyvanse, as well as setbacks in clinical trials for lung cancer and Crohn's disease treatments. Despite these hurdles, the company is focused on growth drivers and new product launches, which are projected to account for around half of its revenue. Looking ahead, Takeda forecasts a modest growth rate of 2% for the current fiscal year, a deceleration from the nearly 6% growth observed in the previous fiscal year. The company's stock has seen a modest increase in response to the restructuring announcement.


Other news in health